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Interaction Among Risk-Time
and Benefit of Primary Angioplasty
We read with interest the study by Brodie et al. (1) showing that
delays in door-to-balloon time have an impact on survival in
high-risk patients with ST-segment elevation myocardial infarc-
tion (STEMI) treated by primary percutaneous coronary interven-
tion (pPCI). We have the following concerns in relation to the
reported results and conclusions in this single-center study.
In the current study, symptom-onset-to-balloon time was not
included in the multivariate analyses. Considering that door-to-
balloon time is significantly related to outcome only in patients
with symptom onset less than 3 h when a striking benefit of
reperfusion is present (1), it is very likely that the exclusion of total
ischemic time from the multivariate analyses would have influ-
enced the results. To this regard, in the single-center study conducted
by De Luca et al. (2), door-to-balloon time was not related to
outcome independently by the risk of the patients, but symptom-
onset-to-balloon time and patent infarct-related artery remained
independent predictors of 1-year survival in high-risk patients with
STEMI. Indeed, Brodie et al. (1) did not take into account in their
analyses the patency of the infarct-related artery at index angiog-
raphy that was present in one-fifth of patients.
Finally, the results may be further biased by the fact that longer
door-to-balloon times were observed in sicker patients treated by
pPCI with a limited use of stents and abciximab (less than 30%)
that are not representative of the actual worldwide standard.
Finally, although losing time appears to be prognostically less
important in low-risk patients than in high-risk patients with
STEMI treated by pPCI, when immediate thrombolysis is feasi-
ble, delaying PCI may be particularly disadvantageous in low-risk
patients (3). On the contrary, a longer delay could be justified to
choose pPCI for high-risk patients, despite the increased risk
associated with delay according to the previously reported “risk-
time-benefit” relationship (3).
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REPLY
Our study (1) analyzed the relationship between door-to-balloon
time and mortality rather than symptom-balloon time because
door-to-balloon time is the strongest predictor of mortality and
because we have influence over door-to-balloon time. We did not
include symptom-balloon time in the multivariable analysis be-
cause symptom-balloon time is correlated with door-to-balloon
time. Either is a significant predictor of mortality when included in
the model alone. When both are included, symptom-balloon time
is no longer a significant predictor of mortality.
We evaluated the relationship between door-to-balloon time
and mortality 1) in patients who had Thrombolysis In Myocardial
Infarction (TIMI) 0 to 1 flow in the infarct artery on initial
angiography and 2) in patients treated since 1996 when stents and
glycoprotein (GP) IIb/IIIa inhibitors were standard care. The
results in these two groups were similar to the group as a whole.
Therefore, we do not believe that inclusion of patients with TIMI
2 to 3 flow on initial angiography and patients treated before the
availability of stents and GPIIb/IIIa inhibitors affected our results.
We disagree with Tarantini and colleagues that “delaying
(percutaneous coronary intervention) PCI may be particularly
disadvantageous in low-risk patients.” We agree that primary PCI
probably offers no mortality advantage over fibrinolytic therapy in
low-risk patients, but our data and the data of others clearly show
that time delays to primary PCI have little impact on mortality in
low-risk patients. In low-risk patients presenting to noninterven-
tional hospitals, transfer to an interventional facility for PCI avoids
the risk of bleeding and intracranial hemorrhage from fibrinolytic
therapy and results in fewer strokes and less reinfarction.
We agree with Tarantini et al. that the absolute mortality
benefit of PCI over fibrinolytic therapy is considerable in high-risk
patients, and this advantage may justify longer delays to PCI.
However, our data show that these delays do have a major impact
on mortality, especially in patients who present early. The hope has
been that, in patients who present to noninterventional hospitals,
with long delays to primary PCI, early pharmacologic reperfusion
therapy followed by transfer for PCI (facilitated PCI) would
establish earlier reperfusion and reduce mortality. Unfortunately,
the recently published ASSENT-4 PCI (Assessment of the Safety
and Efficacy of a New Treatment Strategy with Percutaneous
Coronary Intervention) study showed worse, rather than better,
outcomes with tenecteplase-facilitated PCI (2). There are several
possible reasons for this, and it is possible that future trials with
facilitated PCI using alternative pharmacologic therapies (such as
FINESSE [Facilitated Intervention for Enhanced Reperfusion
Speed to Stop Ischemic Events]) may prove beneficial, especially in
high-risk patients presenting early after the onset of symptoms
who have long delays to PCI. Until we have more data, the best
strategy for high-risk patients who present early to noninterven-
tional hospitals with very long delays to primary PCI may be local
fibrinolytic therapy followed by transfer to an interventional facility
for rescue PCI if needed. In high-risk patients who present later,
the best strategy may be transfer for primary PCI without
fibrinolytic therapy, even with longer delays to PCI.
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